Please Wait...

Grünenthal Selects BioClinica OnPoint Clinical Trial Management System

– Leading Pain Management Company Standardizes on BioClinica CTMS Technology –

March 5, 2012

March 5, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Grünenthal GmbH has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials. BioClinica OnPoint CTMS helps clinical trial sponsors to easily consolidate their data, share this data and improve trial management by using Microsoft SharePoint 2010 and Microsoft Office 2010.

Grünenthal selected BioClinica OnPoint after a thorough evaluation of the leading enterprise-scale CTMS solutions. The assessment team was comprised of Grünenthal experts from various functional areas. The workshops demonstrated that the requirements specified by Grünenthal could be delivered faster and most cost-effectively using OnPoint. Grünenthal was particularly impressed with BioClinica's ability to integrate with other clinical systems, the extensibility of this consolidated data via SharePoint-based dashboards and the fact that OnPoint allows clinical staff to do much of their work within the familiar environment of Microsoft Office applications.

"After careful review of the commercially available CTMS solutions, we felt that BioClinica's platform provides our clinical staff with a timely and comprehensive overview of relevant data and thus helps to make planning more efficient," said Hazel Collie, Head of Quality & Systems at Grünenthal. "In this regard, OnPoint supports our objective to enhance our innovation process, allowing us to develop solutions to improve the quality of life of our patients."

"Life sciences companies of all sizes face increased pressure to efficiently manage clinical trials while bringing drugs to market quickly," said Andrea McGonigle, managing director, Life Sciences, Microsoft Corp. "BioClinica uses Microsoft SharePoint and Office to help clients gain a comprehensive, real-time view into trial performance and act on that information."

Mark Weinstein, CEO of BioClinica, said, "We are proud to be selected to support Grünenthal's clinical trial support needs, world-wide. This agreement demonstrates the results of our continuing commitment to deliver innovative technology solutions that help customers execute and manage their clinical trials with greater efficiency and speed."

About the Grünenthal Group
The Grünenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and to be a leader in therapy innovation. Altogether, the Grünenthal Group has affiliates in 30 countries worldwide. Grünenthal products are sold in more than 150 countries and approx. 4,500 employees are working for the Grünenthal Group globally. In 2010, Grünenthal reached revenues of about 910M €. For more information: www.grunenthal.com.

About Bioclinica
Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval.  The company’s cloud-based offerings include medical imaging, cardiac safety, randomization and trial supply management and optimization, electronic and eSource data capture, site payments and forecasting, pharmacovigilance, trial management, and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development.  The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia. Learn more about Bioclinica at www.Bioclinica.com and on Bioclinica LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Handy guide for the pharmacovigilance folks! https://t.co/tOyQWkiNhW
bioclinica (Yesterday)
#ClinicalResearch sites, REJOICE @bioclinica SMART Submit 4 cloud rsch image mgmt /subm is here! @OutsourcPharmahttp://ow.ly/odCh30grhnY
bioclinica (Yesterday)
What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam! https://t.co/ICngaxA9mg https://t.co/SXxPj3NpD2
bioclinica (2 days ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme… https://t.co/wHfWHtI7sj
bioclinica (3 days ago)
Another CRO seeing big gains in the sites payments process! Access the Case Study here https://t.co/jsCxhmKcLo https://t.co/LpIKEtBKtE
bioclinica (3 days ago)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (4 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices